HC Wainwright Predicts NextCure FY2029 Earnings

NextCure, Inc. (NASDAQ:NXTC) – HC Wainwright issued their FY2029 earnings per share estimates for NextCure in a report released on Friday, March 7th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($0.55) per share for the year. HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for NextCure’s current full-year earnings is ($1.87) per share.

NextCure (NASDAQ:NXTC) last released its earnings results on Thursday, March 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.07).

NextCure Price Performance

Shares of NXTC stock opened at $0.69 on Monday. NextCure has a one year low of $0.66 and a one year high of $2.57. The stock has a fifty day moving average price of $0.78 and a 200 day moving average price of $1.10. The stock has a market cap of $19.41 million, a P/E ratio of -0.33 and a beta of 0.71.

Hedge Funds Weigh In On NextCure

Hedge funds and other institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC raised its position in NextCure by 40.6% in the fourth quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock worth $61,000 after purchasing an additional 22,724 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of NextCure by 14.2% in the 3rd quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock valued at $307,000 after purchasing an additional 27,812 shares during the period. Tang Capital Management LLC raised its holdings in shares of NextCure by 7.3% in the 4th quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock worth $540,000 after buying an additional 47,614 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of NextCure by 27.9% during the 4th quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock worth $400,000 after buying an additional 113,300 shares during the period. Finally, Peapod Lane Capital LLC acquired a new stake in NextCure in the 4th quarter valued at $311,000. 42.65% of the stock is owned by institutional investors.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.